MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MASCT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular immunotherapy is under development for the treatment of soft tissue sarcoma including leiomyosarcoma, liposarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, malignant peripheral nerve sheath, fibrosarcoma, pleomorphic rhabdomyosarcoma, endometrial stromal sarcoma, desmoplastic small round cell tumor, bladder cancer, osteosarcoma, pancreatic cancer, nasopharyngeal cancer, urothelial cell carcinoma, bile duct cancer (cholangiocarcinoma), bladder cancer, ureter cancer, renal cell cancer and urethral cancer. It is administered as intravenous drip and through subcutaneous route. The therapeutic candidate constitutes autologous dendritic cells loaded with antigens called as multiple antigens specific cellular therapy (MASCT). It was also under development for hepatocellular carcinoma, gastric cancer, gastroesophageal adenocarcinoma, triple-negative breast cancer, ovarian cancer, adenocarcinoma of the gastroesophageal junction, advanced solid tumors including lung cancer, colon cancer, prostate cancer,
Hengrui Yuanzheng Biotechnology overview
Hengrui Yuanzheng Biotechnology is a biopharmaceutical company that develops multiple product pipelines including MASCT, TCR-T double-antibody for patients with solid tumors. It is headquartered in Shanghai, China.
For a complete picture of MASCT’s drug-specific PTSR and LoA scores, buy the report here.